Movement Alert｜GENSCRIPT BIO Rises 5.15% in Regular Trading, CARVYKTI Q2 Sales Surge Nearly 50% YoY Combined with Pipeline Progress

Market Focus

1 hour ago

On August 4, GENSCRIPT BIO rose 5.15% in regular trading, trading at HKD 17.67 per share, with turnover of HKD 106 million.

On the news front, the company's associate Legend Biotech previously disclosed that CARVYKTI generated net trade sales of approximately USD 657 million for the quarter ended June 30, representing a nearly 50% year-over-year increase and sustaining strong growth momentum. The sales figure was provided by partner Janssen Biotech under their collaboration and license agreement signed in December 2017.

Additionally, Legend Biotech's investigational in vivo CD19/CD20 dual-target CAR-T therapy LB2501 achieved a 100% objective response rate in a Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma patients, with no dose-limiting toxicities observed. The combination of robust commercial performance and positive pipeline advancement continues to support investor sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1112377946"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1112377946\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1112377946?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-04 09:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112377946","market":"us","top_or_hot":-1,"title":"Movement Alert｜GENSCRIPT BIO Rises 5.15% in Regular Trading, CARVYKTI Q2 Sales Surge Nearly 50% YoY Combined with Pipeline Progress","media":"Market Focus","content":"<p><p>On August 4, GENSCRIPT BIO rose 5.15% in regular trading, trading at HKD 17.67 per share, with turnover of HKD 106 million.</p><p>On the news front, the company's associate Legend Biotech previously disclosed that CARVYKTI generated net trade sales of approximately USD 657 million for the quarter ended June 30, representing a nearly 50% year-over-year increase and sustaining strong growth momentum. The sales figure was provided by partner Janssen Biotech under their collaboration and license agreement signed in December 2017.</p><p>Additionally, Legend Biotech's investigational in vivo CD19/CD20 dual-target CAR-T therapy LB2501 achieved a 100% objective response rate in a Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma patients, with no dose-limiting toxicities observed. The combination of robust commercial performance and positive pipeline advancement continues to support investor sentiment.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜GENSCRIPT BIO Rises 5.15% in Regular Trading, CARVYKTI Q2 Sales Surge Nearly 50% YoY Combined with Pipeline Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜GENSCRIPT BIO Rises 5.15% in Regular Trading, CARVYKTI Q2 Sales Surge Nearly 50% YoY Combined with Pipeline Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-04 09:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 4, GENSCRIPT BIO rose 5.15% in regular trading, trading at HKD 17.67 per share, with turnover of HKD 106 million.</p><p>On the news front, the company's associate Legend Biotech previously disclosed that CARVYKTI generated net trade sales of approximately USD 657 million for the quarter ended June 30, representing a nearly 50% year-over-year increase and sustaining strong growth momentum. The sales figure was provided by partner Janssen Biotech under their collaboration and license agreement signed in December 2017.</p><p>Additionally, Legend Biotech's investigational in vivo CD19/CD20 dual-target CAR-T therapy LB2501 achieved a 100% objective response rate in a Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma patients, with no dose-limiting toxicities observed. The combination of robust commercial performance and positive pipeline advancement continues to support investor sentiment.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1112377946","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112377946","pubTimestamp":1785807528,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 4, GENSCRIPT BIO rose 5.15% in regular trading, trading at HKD 17.67 per share, with turnover of HKD 106 million.On the news front, the company's associate Legend Biotech previously...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"走势提醒|金斯瑞生物常规交易上涨 5.15%，CARVYKTI 第二季度销售额同比飙升近 50%，加上管道进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"On August 4, GENSCRIPT BIO rose 5.15% in regular trading, trading at HKD 17.67 per share, with turnover of HKD 106 million.On the news front, the company's associate Legend Biotech previously disclosed that CARVYKTI generated net trade sales of approximately USD 657 million for the quarter ended June 30, representing a nearly 50% year-over-year increase and sustaining strong growth momentum. The sales figure was provided by partner Janssen Biotech under their collaboration and license agreement signed in December 2017.Additionally, Legend Biotech's investigational in vivo CD19/CD20 dual-target CAR-T therapy LB2501 achieved a 100% objective response rate in a Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma patients, with no dose-limiting toxicities observed. The combination of robust commercial performance and positive pipeline advancement continues to support investor sentiment.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}